Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Gland Pharma Ltd

GLAND.NS ✓ COMPLIANT ☆ Track — members

NSE India · Healthcare · Pharmaceuticals ·

India Mid Cap Analyst: BUY

Last Close

$31.12

▲ +0.09%

Market Cap $5.13B · Vol 789.57K

Key Metrics

P/E Ratio

43.43

FWD: 34.53

Market Cap

$5.13B

Mid Cap

Div Yield

0.67%

Annual dividend

EPS Growth

+26.19%

YoY

RSI (14)

84.74

Momentum

Beta

0.24

vs Market

52W High

$31.85

2.29% below

52W Low

$16.49

83.61% above

Volume

789.57K

Avg 799.09K

P/B

2.70

Price-to-book

ROE

10.78%

Return on equity

Free Float

48.23%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Gland Pharma Ltd (GLAND.NS) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GLAND.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+14.19%

+19.37%

+56.47%

+66.79%

YTD

+72.49%

+50.33%

+61.49%

-30.72%

Financials & Valuation

TTM · Annual

Total Revenue	$688.09M
Net Income	$109.92M
Revenue Growth (YoY)	+19.57%
Gross Margin	54.51%
Operating Margin	18.76%
Net Profit Margin	15.98%
ROE	10.78%
ROA · ROIC	12.34% · 10.30%

P/E Ratio	43.43
Forward P/E (FY1)	34.53
PEG Ratio	0.58
P/S	4.35
P/B	2.70
P/FCF	37.97
EPS Growth	+26.19%
Outstanding Shares	164.97M

Technical Indicators

50-Day SMA	$25.72
200-Day SMA	$20.65
RSI (14)	84.74
Beta	0.24
52-Week High	$31.85
52-Week Low	$16.49

Volume Today	789.57K
Avg Daily Volume (30D)	799.09K
Relative Volume	0.99x
Volatility (10D)	46.68
Volatility (30D)	38.71
Free Float	48.23%

Analyst Consensus

BUY

Current Price $31.12

Mean Target $29.69

52W Low$16.49 52W High$31.85

Current

Target

$16.49 $31.85

Current Analyst target

-4.59% downside risk · 15 analysts

Identifiers

ExchangeNSE India

FIGIBBG001TTNQV5

ISININE068V01023

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateNov 3, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LLY Eli Lilly and Co -2.39% JNJ Johnson & Johnson -0.66% ABBV Abbvie Inc -0.54% NVS Novartis AG -0.55% NOVN.S Novartis AG -1.05%

Company Profile

Gland Pharma Limited is an India-based generic injectables manufacturer. The Company specializes in sterile injectables, oncology, and ophthalmic, with a specific focus on complex injectables, New Chemical Entities (NCE)-1s, First-to-File products, and 505(b)(2) filings. The Company manufactures a range of dosage formulations, including solutions, suspensions, and lyophilized products. Its product portfolio includes delivery methods such as pre-filled syringes, vials, ampoules, bags, and dry powder injections. It also produces generic injectables in liquid, lyophilized, suspension, and pre-filled syringe forms. Its molecules include Enoxaparin Sodium, Cisplatin, Lacosamide, Rocuronium Bromide, Zoledronic Acid, Vancomycin, and others. Its therapeutic products categories include Anti Malarials, Anti-Infectives, Anti-Neoplastics, Gynecological, Hormones, and others. The Company functions primarily on a business-to-business model. Its subsidiary is Gland Pharma International Pte. Ltd.